找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Urothelial Carcinoma; Methods and Protocol Michèle J. Hoffmann,Nadine T. Gaisa,Thorsten H. Ec Book 2023Latest edition The Editor(s) (if app

[復(fù)制鏈接]
樓主: Hazardous
11#
發(fā)表于 2025-3-23 12:07:24 | 只看該作者
12#
發(fā)表于 2025-3-23 14:29:30 | 只看該作者
13#
發(fā)表于 2025-3-23 19:35:09 | 只看該作者
Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for urine (cell-free DNA from the urine supernatant or DNA from exfoliated cells in the urine pellet) has demonstrated promising evidence as putative non-invasive biomarkers for UC detection and monitoring. However, detecting these tumour-derived mutations in urine requires highly sensitive methods, ca
14#
發(fā)表于 2025-3-24 02:08:03 | 只看該作者
Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancerder cancer. Despite a survival benefit, approximately half of patients do not respond to chemotherapy and are exposed potentially unnecessarily to substantial toxicity and delay in surgery. Therefore, biomarkers to identify likely responders before initiating chemotherapy would be a helpful clinical
15#
發(fā)表于 2025-3-24 03:26:56 | 只看該作者
Assessment of PD-L1 Status in Urothelial Canceric urothelial cancer. By PD-1 and PD-L1 inhibition with these drugs, the immune system is supposed to regain the capacity to actively kill cancer cells. Meanwhile, PD-L1 assessment is prescribed for patients not being eligible for platinum-based chemotherapy in first-line settings in metastatic dise
16#
發(fā)表于 2025-3-24 08:59:29 | 只看該作者
17#
發(fā)表于 2025-3-24 13:00:00 | 只看該作者
18#
發(fā)表于 2025-3-24 18:25:23 | 只看該作者
19#
發(fā)表于 2025-3-24 21:14:28 | 只看該作者
Genome-Wide CRISPR Screening for the Identification of Therapy Resistance-Associated Genes in Urotheresistance mechanisms to CDK4/6 inhibition in bladder cancer along with next-generation sequencing (NGS) analysis. We will describe the approach for transcriptional activation in the bladder cancer cell line T24 and provide guidance on critical points during the experimental workflow.
20#
發(fā)表于 2025-3-25 01:50:52 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-20 16:41
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
怀来县| 铁岭市| 定日县| 汕尾市| 墨玉县| 凉城县| 富顺县| 含山县| 上栗县| 建德市| 休宁县| 彩票| 丰城市| 平罗县| 泰州市| 民勤县| 乐平市| 武宣县| 贡山| 韶山市| 临汾市| 丰城市| 广东省| 南江县| 昭苏县| 运城市| 商水县| 大竹县| 科尔| 轮台县| 巢湖市| 大余县| 沙坪坝区| 舞钢市| 昭觉县| 阜新| 兴海县| 榆林市| 武川县| 偏关县| 镇赉县|